Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Saved in:
| Title: | Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". |
|---|---|
| Authors: | Kanzaki H; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.; Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA., Hoshida Y; Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. |
| Source: | Clinical and molecular hepatology [Clin Mol Hepatol] 2025 Jan; Vol. 31 (1), pp. 308-310. Date of Electronic Publication: 2024 Aug 30. |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Korean Association for the Study of the Liver Country of Publication: Korea (South) NLM ID: 101586730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2287-285X (Electronic) Linking ISSN: 22872728 NLM ISO Abbreviation: Clin Mol Hepatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 2287-285X |
|---|---|
| DOI: | 10.3350/cmh.2024.0726 |
